Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash & Equivalents (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Cash & Equivalents data on record, last reported at $2.9 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 38.74% year-over-year to $2.9 million; the TTM value through Sep 2025 reached $2.9 million, down 38.74%, while the annual FY2024 figure was $8.7 million, 30.74% down from the prior year.
  • Cash & Equivalents reached $2.9 million in Q3 2025 per CRVS's latest filing, down from $14.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $31.5 million in Q1 2022 and bottomed at $2.9 million in Q3 2025.
  • Average Cash & Equivalents over 4 years is $13.7 million, with a median of $12.6 million recorded in 2023.
  • The widest YoY moves for Cash & Equivalents: up 93.8% in 2024, down 76.72% in 2024.
  • A 4-year view of Cash & Equivalents shows it stood at $13.2 million in 2022, then decreased by 4.1% to $12.6 million in 2023, then tumbled by 30.74% to $8.7 million in 2024, then crashed by 67.2% to $2.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $2.9 million in Q3 2025, $14.7 million in Q2 2025, and $5.0 million in Q1 2025.